I-MAK filed the first-ever U.S. patent challenges against sofosbuvir, the backbone of Sovaldi®, Harvoni®, and Epclusa®, arguing that the drug’s core patents do not meet the legal standards for novelty and non-obviousness. If Gilead’s eight patents are overturned, U.S. taxpayers will save more than $10 billion and generics will come to market 16 years earlier.
US Cases on Hepatitis C Medicines
Summary of Patents Challenged Patent Number: 7,429,572 Patent Type: Base Family: Clark Expiry: 4/3/2025 Summary: Sofosbuvir is the backbone of all Gilead’s hepatitis C treatments. The core molecule in sofosbuvir is a nucleoside compound. Years before Gilead filed its patents, nucleosides like sofosbuvir already existed in relation to antiviral and anticancer treatments. The core molecule in sofosbuvir…
Global Cases on Hepatitis C Medicines
SOFOSBUVIR China: Base Patent Patent International Publication Number: WO2005003147 Case Type: Invalidation Case Status: Filed on April 18, 2017. In August 2018, Gilead withdrew 12 of the 16 patent claims on the base compound with the Chinese National Intellectual Property Association (CNIPA, formerly State Intellectual Property Office, SIPO). This outcome effectively creates an opportunity for…
Learn more about how you can help build a more equitable system for all